LOXL2 and inflammatory bowel disease: Interestingly, the serum levels of LOXL2 are significantly higher in primary sclerosing cholangitis (PSC) (Pollheimer et al., 2018), which is closely associated with IBD, and LOXL2 targeting in IBD has been evaluated in PSC (Lynch et al., 2019).